Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Green

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Bioorganic & Medicinal Chemistry Letters|December 13, 2005
SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitorsNicola M Heron, Malcolm Anderson, David P Blowers, et al.
Molecular Cancer Therapeutics|September 12, 2015
AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous SchedulesSylvie M Guichard, Jon Curwen, Teeru Bihani, et al.
The Journal of Bone and Joint Surgery. American Volume|March 1, 2017
Investigation of Taper Failure in a Contemporary Metal-on-Metal Hip Arthroplasty System Through Examination of Unused and Explanted ProsthesesDavid Langton, Imran Ahmed, Peter Avery, et al.
Bioorganic & Medicinal Chemistry Letters|October 18, 2015
Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancersBernard Barlaam, Sabina Cosulich, Bénédicte Delouvrié, et al.
Molecular Cancer Therapeutics|September 16, 2008
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapiesSonya D Zabludoff, Chun Deng, Michael R Grondine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2007
AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosisRobert W Wilkinson, Rajesh Odedra, Simon P Heaton, et al.
Molecular Cancer Therapeutics|November 16, 2014
Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxelUrs Hancox, Sabina Cosulich, Lyndsey Hanson, et al.
Journal of Medicinal Chemistry|February 3, 2006
Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitorsFrédéric H Jung, Georges Pasquet, Christine Lambert-van der Brempt, et al.
Medchemcomm|October 18, 2016
Discovery of 4,6-disubstituted pyrimidines as potent inhibitors of the heat shock factor 1 (HSF1) stress pathway and CDK9Carl S Rye, Nicola E A Chessum, Scott Lamont, et al.
Journal of Medicinal Chemistry|March 22, 2007
Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinaseAndrew A Mortlock, Kevin M Foote, Nicola M Heron, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Bioorganic & Medicinal Chemistry Letters|December 13, 2005
SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitorsNicola M Heron, Malcolm Anderson, David P Blowers, et al.
Molecular Cancer Therapeutics|September 12, 2015
AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous SchedulesSylvie M Guichard, Jon Curwen, Teeru Bihani, et al.
The Journal of Bone and Joint Surgery. American Volume|March 1, 2017
Investigation of Taper Failure in a Contemporary Metal-on-Metal Hip Arthroplasty System Through Examination of Unused and Explanted ProsthesesDavid Langton, Imran Ahmed, Peter Avery, et al.
Bioorganic & Medicinal Chemistry Letters|October 18, 2015
Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancersBernard Barlaam, Sabina Cosulich, Bénédicte Delouvrié, et al.
Molecular Cancer Therapeutics|September 16, 2008
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapiesSonya D Zabludoff, Chun Deng, Michael R Grondine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2007
AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosisRobert W Wilkinson, Rajesh Odedra, Simon P Heaton, et al.
Molecular Cancer Therapeutics|November 16, 2014
Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxelUrs Hancox, Sabina Cosulich, Lyndsey Hanson, et al.
Journal of Medicinal Chemistry|February 3, 2006
Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitorsFrédéric H Jung, Georges Pasquet, Christine Lambert-van der Brempt, et al.
Medchemcomm|October 18, 2016
Discovery of 4,6-disubstituted pyrimidines as potent inhibitors of the heat shock factor 1 (HSF1) stress pathway and CDK9Carl S Rye, Nicola E A Chessum, Scott Lamont, et al.
Journal of Medicinal Chemistry|March 22, 2007
Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinaseAndrew A Mortlock, Kevin M Foote, Nicola M Heron, et al.
Pageof 6